Join our comprehensive program tailored to provide personalized education based on your existing knowledge on the latest evidence in the frontline treatment of locally advanced or metastatic bladder cancer. Through this program, you’ll gain insights into evaluating clinical data on the safety and efficacy of guideline-recommended therapies, applying the latest evidence to guide treatment selection and sequencing, and employing strategies for multidisciplinary care coordination to ensure patient-centered care that aligns with individual preferences, goals, and quality of life. Test your knowledge, receive real-time feedback, and create your own unique experience available with a curated, downloadable resource upon completion based on your current level of knowledge.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/deep-dive-new-emerging-evidence-first-line-treatment-advanced-metastatic
- Start Date: 2024-12-12 06:00:00
- End Date: 2024-12-12 06:00:00
- Credit Details: IPCE Credits: 0.5 hours
AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - Commercial Support: Source: Merck (Any division) - Amount: 79500.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all